Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to
patients with severe primary pulmonary hypertension for whom no alternative therapy is
available.
II. Obtain additional safety information on continuous infusion epoprostenol. III. Obtain
additional information on economic resource health consumption.